Sonnet BioTherapeutics (SONN) News Today $2.96 +0.04 (+1.37%) (As of 01:40 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Sonnet BioTherapeutics releases ‘What this Means’ segmentNovember 13, 2024 | markets.businessinsider.comSonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” SegmentNovember 12, 2024 | globenewswire.comSonnet BioTherapeutics secures US patent covering two drug candidatesNovember 8, 2024 | finance.yahoo.comSonnet BioTherapeutics prices $5M at-the-market offeringNovember 7, 2024 | markets.businessinsider.comSonnet BioTherapeutics (NASDAQ:SONN) Stock Quotes, Forecast and News SummaryNovember 6, 2024 | benzinga.comSonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug CandidatesNovember 6, 2024 | globenewswire.comSonnet BioTherapeutics Inc. Regains Compliance with NasdaqOctober 17, 2024 | globenewswire.comSonnet BioTherapeutics’ Strategic Deal to Develop DPN TreatmentOctober 10, 2024 | finance.yahoo.comSonnet Partners Alkem To Develop And Market SON-080 For Diabetic Peripheral Neuropathy In IndiaOctober 10, 2024 | markets.businessinsider.comSonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in IndiaOctober 9, 2024 | globenewswire.comSonnet BioTherapeutics secures tax credit approvalOctober 6, 2024 | investing.comSonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive ProgramsOctober 4, 2024 | globenewswire.comSonnet BioTherapeutics Announces Launch of CEO Corner PlatformSeptember 30, 2024 | globenewswire.comSonnet BioTherapeutics To Effect 1-for-8 Reverse Stock SplitSeptember 25, 2024 | markets.businessinsider.comWhy Sonnet BioTherapeutics (SONN) Shares Are Down 19% TodaySeptember 25, 2024 | msn.comSonnet BioTherapeutics Announces 1-for-8 Reverse Stock SplitSeptember 25, 2024 | globenewswire.comSonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid TumorsSeptember 18, 2024 | globenewswire.comSonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell SeriesSeptember 4, 2024 | globenewswire.comSonnet BioTherapeutics Holdings, Inc. (SONN)August 27, 2024 | finance.yahoo.comAnalysts’ Top Healthcare Picks: Sonnet BioTherapeutics Holdings (SONN), Agilent (A)August 26, 2024 | markets.businessinsider.comSonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic CancerAugust 19, 2024 | globenewswire.comSonnet BioTherapeutics Holdings, Inc.: Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate UpdateAugust 16, 2024 | finanznachrichten.deSONN Stock Earnings: Sonnet BioTherapeutics Beats EPS for Q3 2024August 14, 2024 | investorplace.comSonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate UpdateAugust 14, 2024 | globenewswire.comJTC Team, LLC: Sonnet BioTherapeutics Participates in Virtual Investor "What This Means" Segment Hosted by JTC TeamJuly 25, 2024 | finanznachrichten.deSonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 StudyJuly 24, 2024 | globenewswire.comSonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual MeetingMay 28, 2024 | globenewswire.comSonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Announces Review of Strategic AlternativesMay 22, 2024 | finanznachrichten.deSonnet BioTherapeutics Announces Review of Strategic AlternativesMay 22, 2024 | finance.yahoo.comSONN Stock Earnings: Sonnet BioTherapeutics Misses EPS for Q2 2024May 15, 2024 | investorplace.comAnalysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM) and HCA Healthcare (HCA)April 28, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), Genmab (GMAB)April 17, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC) and Arcus Biosciences (RCUS)April 12, 2024 | markets.businessinsider.comSonnet BioTherapeutics Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study’s Initial Pre-Specified ObjectiveMarch 11, 2024 | finance.yahoo.comSonnet BioTherapeutics Holdings Inc Ordinary Shares SONNMarch 1, 2024 | morningstar.comSonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy VolunteersFebruary 29, 2024 | finanznachrichten.deSonnet BioTherapeutics Reported SON-1010 Phase I Trial Results: Demonstrates Safety, Efficacy in Melanoma Model, and Potential for Dose EscalationFebruary 29, 2024 | msn.comSonnet BioTherapeutics Holdings First Quarter 2024 Earnings: Beats ExpectationsFebruary 17, 2024 | finance.yahoo.comSonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings UpdateFebruary 14, 2024 | finance.yahoo.comNasdaq panel expected to decide on Yield10 listing within next monthFebruary 7, 2024 | msn.comBTIG Keeps Their Buy Rating on Sonnet BioTherapeutics Holdings (SONN)January 1, 2024 | markets.businessinsider.comSonnet BioTherapeutics files for $100M mixed shelfDecember 22, 2023 | msn.comSonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor ImmunotherapyDecember 21, 2023 | finance.yahoo.comBuy Rating Affirmed for Sonnet BioTherapeutics Amid Promising Oncology Trials and Financial FortitudeDecember 16, 2023 | markets.businessinsider.comSonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial UpdateDecember 14, 2023 | finance.yahoo.comSonnet BioTherapeutics Provides Fiscal Year 2023 Business OverviewOctober 31, 2023 | finance.yahoo.comWhat's Happening With Sonnet BioTherapeutics (SONN) Shares?October 26, 2023 | benzinga.comDow Falls Over 100 Points; Alphabet Shares Tumble After Q3 ResultsOctober 25, 2023 | markets.businessinsider.comSonnet BioTherapeutics down 32%, prices $4.55M stock offeringOctober 25, 2023 | msn.comWhy Sonnet BioTherapeutics (SONN) Stock Is Getting HammeredOctober 25, 2023 | benzinga.com Get Sonnet BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SONN and its competitors with MarketBeat's FREE daily newsletter. Email Address [625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen. Register for the FREE Workshop Now & get $10 in Bitcoin SONN Media Mentions By Week SONN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SONN News Sentiment▼0.000.47▲Average Medical News Sentiment SONN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SONN Articles This Week▼00▲SONN Articles Average Week Get Sonnet BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SONN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Moleculin Biotech News Today Coeptis Therapeutics News Today Galecto News Today Alterity Therapeutics News Today Syros Pharmaceuticals News Today Brainstorm Cell Therapeutics News Today Biora Therapeutics News Today Can-Fite BioPharma News Today ABVC BioPharma News Today Evoke Pharma News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SONN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonnet BioTherapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonnet BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
